Dual PPAR α/γ Agonism Normalizes Lipoprotein Profile of Renal Dyslipidemia

Table 4

Plasma concentrations of lipoprotein subclasses (mg/dL) in patients with chronic renal insufficiency (n = 23) and healthy reference subjects (n = 17) at start and end of treatment with 1 mg tesaglitazar o.d. Mean and standard (in parenthesis).

	CKD patients			Healthy reference group
	At entry	After 6 weeks	Estimated change	At entry	After 6 weeks	Estimated change
Lp-A-I	36 (5)	40 (6)	+11%**	37 (7)	37 (7)	−1%
Lp-A-I : A-II	105 (12)	114 (17)	+8%**	108 (20)	117 (15)	+10%
Lp-B	79 (18)	67 (19)	−17%***	67 (11)	58 (10)	−13%**
Lp-B : C	10 (8)	7 (3)	−26%*	6 (2)	5 (2)	−19%
Lp-B : E + Lp-B : C : E	20 (8)	14 (6)	−28%**	13 (6)	10 (4)	−11%
Lp-A-II : B : C : D : E	17 (7)	16 (9)	−9%	20 (9)	15 (8)	−29%*

∗P < 0.05, **P < 0.01, and ***P < 0.001 with group comparison between baseline and after 6 weeks of treatment.